Expresión de los receptores de estrógenos, progesterona y Her2/neu en muestras de tejido con diagnóstico histopatológico de carcinoma de mama
Contenido principal del artículo
Resumen
carcinoma de mama es la neoplasia maligna más frecuente en mujeres a nivel mundial. Establecer un pronóstico es fundamental para las decisiones médicas y manejo de la enfermedad.1 Su diagnóstico se complementa con el estudio de marcadores y factores pronósticos para predecir el riesgo de recurrencia, evolución de la enfermedad y respuesta al tratamiento.
Detalles del artículo
Sección
Cómo citar
Referencias
Programa de formación continua en medicina 7a. Serie. 1. Medicine México. Enfermedades üncológicas III 2008; 3: 685-49.
Instituto Nacional de Estadística y Geografía; Mujeres y hombres en México 2009. 13a. Ed. México: p. 53-65.
Segunda Revisión de Consenso Nacional sobre Diagnóstico y Tratamiento del Cáncer de Mama. México: 2006, p. 1-45.
Nandi S, Guzmán. Hormones and Mammary Carcinogenesis in mice, rats and Humans: A Unifying hypothesis. Porc Natl Acad 1995; 92: 3650-7.
Clemons M, Goss P. Estrogen and The Risk üf breast Cancer. N Engl Med 2001; 344: 276-85.
Sánchez P. Receptores Estrogénicos Alfa y Beta en el Cáncer de Mama. Acta Médica. Hospital de üncología Centro Médico siglo XXI 2003;
: 159-61.
Singletary E. Rating the risk factors for breast cancer. 2003; 237(4): 474-82.
Torres TR. Tumores malignos. Tumores de Mama Diagnóstico y Tratamiento. Editorial Interamericana Mc Graw Hill; p. 269-78.
Tsuda H. Review Article Her -2 (c-erb-2) Test Update; Present Status and Problems Breast Cancer July 2006; 13: 236-48.
Mc Ghuire W. Estrogen receptor in human breast cancer. J Clin Invest 1973; 52: 73-88.
Allred DC. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. üncologist 2008; 13: 1134-6.
Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor sta-
tus alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin üncol 2003; 21: 1973-9.
Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, Poulsen HS. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays Eur J Cancer 1990; 26: 442-9.
Buzdar A, Vergote I, Sainsbury R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J 2004; 10: 211-17.
Pothos A. Comparision of Chromogenic in situ Hybridization with Flourescence in Situ Hybridization and Immunohistochemistry for the Assessment of Her-2/neu. üncogene in Archival Material of Breast Carcinoma. Acta Histochem and Cytochem 2008; 41(3): 59-64.
Park K. Comparing Fluorescence in situ Hybridization and Chromogenic in situ Hybridization Methods to Determine the HER2/Neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003; 16(9): 937-43.
Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004; 3: 379-98.
Barrena J. Relación de receptores hormonales en el cáncer de mama con variables pronósticas: afectación ganglionar, tipos y grados histológicos, status menopáusico y marcadores tumorales. Clin Invest Gin übst 1997; 24: 84-91.
Ersnter VL, Barlow WE. Detection of ductal carcinoma in situ in women undergoing screening mammography. Deparment of Epidemiology and Bioestadistics, University of California, San Francisco, 2002; 94: 1546-54.
Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: a hypothesisgenerating study. 2005; 23: 7512-17.
Clarke RB. Steroid receptors and proliferation in the human breast. Steroids 2003; 68: 789-94.
Keen JC, Davidson NE. The biology of breast carcinoma 2003; 97(3): 825-33.
Elledge RM, Allred DC. Clinical aspects of estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, üsborne CK (eds). Diseases of the Breast 2004; 3: 602-17.
Anderson E. Progesterone receptors-animal models and cell signaling in breast cancer: The role of estrogen and progesterone receptors in human mammary development and tumor genesis. Breas Cancer Res 2002; 4: 197-201.
Viale G, Regan MM, Maiorano E, et al. Chemo endocrine compared with endocrine adjuvant therapies for node negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors International Breast Cancer Study Group. J Clin üncol 2008; 26: 1404-10.